Head-to-head · WeighScore
Boston Medical Group vs Lumora
The verdict
Lumora takes it — 66.1/100 to 61.9/100.
Lumora grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Lumora |
|---|---|---|
| WeighScore | 61.9/100 | 66.1/100 |
| Grade | C | C |
| Scorecard rank | #279 | #205 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $199/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $299/mo (starting dose, compounded) |
| Coverage | 7 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #205 · C
Strengths
- Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
- Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
- LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
- Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
- Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141
Where it loses points
- Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
- Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
- Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
- No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
- Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.